This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MRE11 / Double-strand break repair protein MRE11 · IHC design guide
Design Immunohistochemistry for MRE11
Plan cell type scoring around MRE11’s ubiquitous nuclear tissue staining (HPA tissue IHC). This paraffin IHC guide pairs that pattern with the catalog antibody’s 2–5 μg/ml range (datasheet A32234).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MRE11 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Ubiquitous nuclear tissue staining (HPA tissue IHC) | |
| Staining pattern | Widespread nuclear staining; high in adipocytes (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A32234) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin specimens (selected-SKU IHC image A32234) | |
| Caveat | Staining has medium concordance with RNA data (HPA tissue IHC) | |
| Regulation | DNA damage recruits MRE11 to break sites (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended MRE11 IHC & IF Protocols
The catalog antibody uses EDTA pH 8.0 heat retrieval (datasheet A32234). Four published MRE11 IHC methods provide the tissue protocols below (PMC4057395; PMC5223425; PMC13544048; PMC13186548).
| Sample | Paraffin-embedded human bladder epithelial carcinoma tissue; fixative not specified (datasheet A32234) |
| Fixation | Image fixative and duration unreported (datasheet A32234); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A32234); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A32234) |
| Primary antibody | Rabbit anti-MRE11, 2-5 μg/ml (datasheet A32234) |
| Primary incubation | Overnight at 4 °C (datasheet A32234) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A32234) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MRE11-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A32234). The laryngeal biopsy methods used pH 9 retrieval (PMC13544048; PMC13186548).
Section 2
What Is the Expected MRE11 Staining Pattern?
MRE11 should appear predominantly in nuclei across many cell types (HPA: ubiquitous nuclear expression; UniProt P49959: nucleus). HPA reports high staining in adipocytes, adrenal and appendix glandular cells, bone marrow hematopoietic cells, bronchial respiratory epithelial cells, caudate glial cells, and cerebellar granular-layer cells (HPA: tissue IHC). Its lack of a transmembrane segment supports an intracellular pattern (UniProt P49959: topology). HPA rates the tissue pattern Supported, with medium consistency against RNA data (HPA: tissue IHC).
| Predominantly nuclear chromogenic staining in the listed positive cell types. | This agrees with the reported tissue pattern (HPA: ubiquitous nuclear expression and listed High cell types) and nuclear location (UniProt P49959). Judge intensity against the matched control and local background; HPA's High category does not specify a universal chromogen intensity or scoring cutoff (HPA: tissue IHC). |
| Distinct nuclear staining with some variation among cells or regions. | Nuclear localization remains the main interpretation criterion (HPA: tissue IHC; UniProt P49959: nucleus). MRE11 also localizes to DNA double-strand breaks and telomeres (UniProt P49959: subcellular location), but routine chromogenic IHC cannot identify those sites from nuclear color alone (standard IHC practice). |
| Predominantly cytoplasmic, membranous, or extracellular staining with little nuclear signal. | Treat this as a suspect compartment pattern or staining artefact (HPA: ubiquitous nuclear expression; UniProt P49959: nucleus, no transmembrane segment). Review the antibody control and detection background before assigning biological meaning; these sources do not establish an expected membrane or secreted MRE11 pattern (UniProt P49959: topology and processing). |
| Strong staining restricted to an unexpected cell population, especially without staining in listed positive cells. | Consider cross-reactivity or endogenous detection activity, and inspect cell identity and compartment with the counterstain (standard IHC practice). Because HPA describes ubiquitous nuclear expression, an unlisted cell type is not automatically negative (HPA: tissue IHC). A nuclear signal in that cell type needs control-based assessment, not rejection by tissue name alone (HPA: tissue IHC). |
| Diffuse color across nuclei, cytoplasm, and surrounding tissue, or no nuclear signal in a listed positive tissue. | Diffuse color weakens confidence in compartment scoring; check background with a no-primary control (standard IHC practice). An absent signal in a listed High cell type warrants review of tissue integrity, detection and antibody conditions (HPA: tissue IHC; standard IHC practice). HPA's Supported rating does not guarantee every section will stain (HPA: reliability summary). |
💡Expected MRE11 appearanceCall a section positive when identifiable cells show predominantly nuclear chromogen above local background, including listed High cell types when present (HPA: tissue IHC; UniProt P49959: nucleus); widespread cytoplasmic or extracellular color without nuclear enrichment is suspect (standard IHC interpretation).
| Compartment and target topology | Nuclear signal is the primary localization check (HPA: ubiquitous nuclear expression; UniProt P49959: nucleus). MRE11 has no annotated transmembrane segment or signal peptide, so a dominant cell-surface or secreted pattern lacks support from this record (UniProt P49959: topology and processing). |
| Tissue distribution and evidence strength | HPA lists multiple High cell populations and low RNA tissue specificity, supporting a broad choice of positive tissue (HPA: tissue IHC). Its tissue reliability is Supported with medium staining–RNA consistency; interpret discrepant sections with controls rather than treating RNA as a cell-level IHC readout (HPA: reliability summary; standard IHC practice). |
| Antibody validation scope | Two listed rabbit polyclonal antibodies, HPA002691 and CAB004081, each have Supported IHC status (HPA: antibody validation). This supports use of their reported patterns as a reference; it does not validate an unlisted antibody, establish an optimal dilution, or prove that every chromogenic signal is specific (HPA: antibody validation; standard IHC practice). |
| Isoforms and epitope coverage | Three isoforms are listed (UniProt P49959: isoforms 1–3). Epitope positions and isoform recognition are absent from the supplied antibody data (HPA: antibody summaries); therefore, staining differences cannot be assigned to a specific isoform. Check the chosen antibody's epitope documentation before making an isoform-specific interpretation (standard IHC practice). |
| Retrieval and detection workflow | Antigen retrieval and endogenous enzyme blocking are general considerations for chromogenic paraffin IHC (standard IHC practice). The supplied HPA and UniProt records give no MRE11-specific retrieval condition, fixation sensitivity, or endogenous detection profile (HPA: supplied tissue and antibody data; UniProt P49959: supplied record). Optimize these steps with appropriate controls. |
| IF/ICC comparison | For the separate IF/ICC guide, HPA reports enhanced nucleoplasmic localization and Supported ICC status for both listed antibodies (HPA: subcellular and antibody data). That observation can inform a localization check, but this IHC section supplies no IF/ICC protocol or fluorescence intensity threshold (HPA: supplied subcellular data). |
| Situation | Likely cause | Next action |
|---|---|---|
| No nuclear stain in a listed High cell type. | The result conflicts with the HPA tissue reference, although a failed section alone cannot identify the failed step (HPA: tissue IHC; standard IHC practice). | Confirm cell identity and tissue preservation, then check a concurrent positive control, antibody application, retrieval and detection steps (standard IHC practice). Do not infer MRE11-specific fixation sensitivity from this result (HPA: supplied tissue data). |
| Only cytoplasmic or membranous color is visible. | The dominant compartment disagrees with nuclear localization and the absence of a transmembrane segment (HPA: tissue IHC; UniProt P49959: topology). | Compare with a no-primary control, inspect counterstained nuclei, and review detection background and antibody specificity (standard IHC practice). Record the pattern as unresolved if nuclear enrichment is still absent. |
| Color appears across the whole section or obscures cell boundaries. | Diffuse background can arise from the staining workflow and prevents reliable compartment assessment (standard IHC practice). | Check the no-primary control and review blocking, washing, detection reagent exposure and chromogen development (standard IHC practice). Reassess nuclear localization only where cells and local background remain distinguishable. |
| Unexpected cells stain while listed positive cells do not. | Cross-reactivity or endogenous detection activity is possible, but HPA's ubiquitous nuclear profile means cell identity alone cannot establish a false positive (HPA: tissue IHC; standard IHC practice). | Verify cell identity with morphology and counterstain; compare compartments in both populations and run a no-primary control (standard IHC practice). Seek independent antibody or orthogonal evidence before assigning the unexpected signal to MRE11 (standard IHC practice). |
| Two antibodies give different distributions. | The supplied data list separate antibodies with Supported IHC status, without epitopes or isoform coverage (HPA: antibody validation; UniProt P49959: three isoforms). | Compare matched sections, controls and nuclear localization, then check each antibody's epitope information (standard IHC practice). Do not attribute the difference to a particular isoform without evidence of recognition. |
| An IF/ICC image seems more punctate than the IHC slide. | HPA describes nucleoplasmic IF localization, while UniProt reports recruitment to DNA double-strand breaks; neither source sets a required chromogenic puncta pattern (HPA: subcellular; UniProt P49959: localization). | Score the paraffin IHC slide for nuclear enrichment and interpretable background (HPA: tissue IHC; standard IHC practice). Use the separate IF/ICC guide for fluorescence-specific controls and interpretation. |
Experiment evidence
IHC & IF images showing MRE11 staining
A32234 · IHCIHC analysis of MRE11 using anti-MRE11 antibody (A32234). MRE11 was detected in a paraffin-embedded section of human bladder epithelial carc
A32234 · IHCIHC analysis of MRE11 using anti-MRE11 antibody (A32234). MRE11 was detected in a paraffin-embedded section of human colonic adenocarcinoma
A32234 · IFIF analysis of MRE11 using anti-MRE11 antibody (A32234). MRE11 was detected in an immunocytochemical section of T-47D cells. Enzyme antigen
A32234-1 · IHCIHC analysis of MRE11 using anti-MRE11 antibody (A32234-1). MRE11 was detected in a paraffin-embedded section of human laryngeal squamous ce
A32234-1 · IHCIHC analysis of MRE11 using anti-MRE11 antibody (A32234-1). MRE11 was detected in a paraffin-embedded section of human thyroid cancer tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000020922-MRE11/tissue/cerebral+cortex#imid_959808
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000020922-MRE11/tissue/colon#imid_959742
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000020922-MRE11/tissue/liver#imid_959735
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000020922-MRE11/tissue/kidney#imid_959744
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA002691; green = MRE11, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA002691; green = MRE11, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MRE11 IHC & IF
🧪Run bone marrow first: hematopoietic cells should show MRE11 staining (HPA: High in bone marrow hematopoietic cells), with signal assessed in nuclei (UniProt P49959: nucleus). HPA detects MRE11 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, while anucleate erythrocytes on the positive slide should lack nuclear signal and serve only as internal staining comparators (HPA: no negative rows; standard IHC practice).
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: MRE11 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MRE11 in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Run a secondary-only control, an immunoglobulin control matched to the primary antibody’s host species and class, and MRE11-knockout material as a biological specificity control (standard IHC practice). Quench endogenous peroxidase in bone marrow, and assess endogenous biotin background if using the caption’s biotin-based detection system (standard IHC practice; selected-SKU caption: biotinylated secondary and SABC/DAB detection).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU paraffin-section caption does not state a fixative (selected-SKU caption: fixative not stated). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish whether retrieval is required for bone marrow (selected-SKU caption: EDTA retrieval); the supplied ICC-IF images do not establish that frozen sections or IF are easier (HPA subcellular: ICC-IF images in A-431, U-251MG and U2OS). Endogenous peroxidase in marrow cells can produce chromogenic background, so interpret nuclear DAB signal against the negative controls (standard IHC practice; UniProt P49959: nucleus).
HPA tissue IHC evidence for MRE11
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Adipocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: MRE11 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced MRE11 IHC Tips
These questions focus on interpreting MRE11 nuclear staining in paraffin sections while keeping antibody specific observations separate from general IHC practice.
Which retrieval conditions should I start with for weak MRE11 staining?
Start with heat mediated antigen retrieval in EDTA at pH 8.0 for this IHC antibody (datasheet A32234). The documented paraffin section was incubated with 2 µg/ml primary antibody overnight at 4°C, so keep that antibody step consistent while assessing retrieval (datasheet A32234). If nuclei remain weak, compare shorter and longer heating within the same EDTA condition, using adjacent sections and recording tissue morphology (standard IHC practice). Excessive heating can damage sections or increase diffuse staining, making nuclear signal harder to judge (standard IHC practice). Score changes against intact nuclei because MRE11 is predominantly nuclear (UniProt P49959; HPA tissue IHC).
Could fixation explain inconsistent nuclear MRE11 staining between sections?
Target specific fixation sensitivity is unknown from the supplied evidence: the A32234 image describes a paraffin section but does not state its fixative (datasheet A32234). Record the fixative, fixation duration, section age, and processing history for each case before attributing a staining difference to MRE11 biology (standard IHC practice). Compare matched sections processed together, with EDTA retrieval at pH 8.0 and a consistent primary incubation of 2 µg/ml overnight at 4°C (datasheet A32234). If nuclear staining varies with processing history, repeat a controlled fixation comparison before changing the antibody concentration (standard IHC practice). Nuclear localisation and annotated modifications alone do not establish a fixation effect (UniProt P49959).
What staining pattern should I expect in a successful MRE11 IHC section?
Expect predominantly nuclear staining: MRE11 is assigned to the nucleus and chromosomes, including telomeres, and can localise to DNA double strand breaks (UniProt P49959). Tissue IHC describes ubiquitous nuclear expression, while subcellular imaging places it in the nucleoplasm (HPA tissue IHC; HPA subcellular). Evaluate signal within morphologically intact nuclei and compare its distribution with the nuclear counterstain across several fields (standard IHC practice). Diffuse cytoplasmic colour without convincing nuclear enrichment warrants checks of detection chemistry, washing, and section integrity before biological interpretation (standard IHC practice; UniProt P49959). A lack of visible repair foci in chromogenic sections alone does not contradict nuclear expression (UniProt P49959; standard IHC practice).
How could epitope placement affect interpretation of MRE11 IHC?
MRE11 has 3 annotated isoforms and multiple modified residues, including phosphorylation and arginine methylation sites (UniProt P49959). The supplied A32234 caption does not identify its epitope, so a difference between specimens cannot be assigned to one isoform or modification from this IHC result alone (datasheet A32234; UniProt P49959). If an epitope map becomes available, check whether it overlaps a variable sequence or modified residue before interpreting staining differences (standard IHC practice; UniProt P49959). Keep retrieval at EDTA pH 8.0 during comparisons and use an independently validated antibody recognising a distinct epitope when isoform or epitope dependence matters (datasheet A32234; standard IHC practice).
How should I investigate MRE11 localisation with multiplex IF?
For an IF follow up, pair MRE11 with a validated marker of the cell population being assessed, so nuclear signal can be assigned to the intended cells (standard IF practice; UniProt P49959). Select spectrally separated fluorophores and place the weaker signal in a channel with low tissue autofluorescence, checking single stain controls before interpreting overlap (standard IF practice). MRE11 has no transmembrane segment and is predominantly nucleoplasmic, so assess nuclear access with a mild permeabilisation pilot after fixation (UniProt P49959; HPA subcellular; standard IF practice). The 2 µg/ml overnight condition comes from paraffin section IHC and requires separate IF optimisation (datasheet A32234; standard IF practice).
How can I reduce diffuse brown signal without losing nuclear staining?
First compare a no primary control with the stained section to locate background from the secondary antibody and chromogenic detection (standard IHC practice). The documented workflow used 10% goat serum blocking, a biotinylated goat anti rabbit secondary for 30 minutes at 37°C, and DAB development (datasheet A32234). Include an endogenous peroxidase block and assess endogenous biotin when using this biotin based detection system (standard IHC practice; datasheet A32234). If background persists, optimise blocking, washes, primary concentration, and DAB development one variable at a time while preserving nuclear signal (standard IHC practice; UniProt P49959). Inspect tissue edges and damaged areas separately because local colour accumulation can distort interpretation (standard IHC practice).
What is a defensible way to score MRE11 in paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define a nuclear scoring rule before examining groups because MRE11 is predominantly nuclear (UniProt P49959; HPA tissue IHC). For chromogenic IHC, record the percentage of positive nuclei and staining intensity by cell population, then calculate an H score if intensity categories are reproducible (standard IHC practice). Alternatively, report positive nuclei per mm² when cell density differs substantially, alongside the total eligible nuclei and sampled area (standard IHC practice). Normalise counts to morphologically intact nuclei in comparable tissue compartments, excluding necrosis and section artefacts by a prespecified rule (standard IHC practice). Use the same retrieval, exposure to DAB, and scoring thresholds across compared sections (datasheet A32234; standard IHC practice).
How do I distinguish genuine MRE11 positivity from staining artefacts?
Genuine staining should be centred on intact nuclei, consistent with MRE11 nuclear localisation and the tissue IHC profile (UniProt P49959; HPA tissue IHC). Confirm which cell population is positive on the counterstained section rather than assigning colour from an adjacent cell to the intended population (standard IHC practice). Treat staining confined to section edges, folds, or necrotic areas as suspect, and compare those regions with intact tissue and a no primary control (standard IHC practice). Check endogenous peroxidase and, for the documented biotin based method, endogenous biotin before accepting unexpected brown signal (datasheet A32234; standard IHC practice). HPA reports supported tissue staining with medium RNA concordance, so concordance is supportive rather than definitive for an individual section (HPA tissue IHC).
Boster reagents
Best MRE11 / Double-strand break repair protein MRE11 IHC Antibodies
Both catalog antibodies have human paraffin-section IHC images (catalog IHC captions); A32234 also has IF/ICC data in T-47D cells (A32234 IF caption). Human, Mouse and Rat reactivity is listed for both (catalog reactivity).
Real IHC data
Anti-MRE11 Antibody ®
Cat # A32234
Real IHC data
Anti-MRE11 Antibody ®
Cat # A32234-1
A32234 will render with an IHC image from human bladder epithelial carcinoma tissue (A32234 IHC caption); its application list includes IF and ICC, with an IF image from T-47D cells (A32234 applications; A32234 IF caption). A32234-1 will render with an IHC image from human laryngeal squamous cell carcinoma tissue (A32234-1 IHC caption); its application list includes IHC (A32234-1 applications).
Which to pick: For paraffin-section IHC, either SKU has a human tissue image using EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody; fixation is unreported in both captions (A32234 IHC caption; A32234-1 IHC caption). Choose A32234 for IF/ICC because those applications and a T-47D IF image are listed for that SKU (A32234 applications; A32234 IF caption). For cross-species tissue IHC, A32234-1 explicitly lists Human, Mouse and Rat for paraffin-section IHC, although its supplied IHC images show human tissue (A32234-1 dilution data; A32234-1 IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P49959 (MRE11_HUMAN, Double-strand break repair protein MRE11).
- Human Protein Atlas. MRE11 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. MRE11 subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. MRE11 antibody validation summary (2 antibodies).
- Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PloS one 2014 — PMC4057395.
- Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC cancer 2017 — PMC5223425.
- Clinical stage-dependent expression of MRE11 and its association with laryngeal cancer progression. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology 2026 — PMC13544048.
- Distinct Association of MRE11 and ATM Co-Expression with Clinical Outcomes in Laryngeal Cancer. Oncology 2026 — PMC13186548.
- PubMed PMID:8530104 — UniProt-cited evidence.
- PubMed PMID:9651580 — UniProt-cited evidence.
- PubMed PMID:11371508 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MRE11 (Double-strand break repair protein MRE11). Expected localisation Ubiquitous nuclear tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A32234). Validated IHC antibody: A32234 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human bladder epithelial carcinoma tissue; fixative not specified (datasheet A32234); 2. Fixation: Image fixative and duration unreported (datasheet A32234); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A32234); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A32234); 8. Primary antibody: Rabbit anti-MRE11, 2-5 μg/ml (datasheet A32234); 9. Primary incubation: Overnight at 4 °C (datasheet A32234). Watch for: Fixation: Keep fixation consistent across paraffin specimens (selected-SKU IHC image A32234); Caveat: Staining has medium concordance with RNA data (HPA tissue IHC); Isoform / epitope: 3 isoforms; epitope coverage is unspecified (UniProt); Regulation: DNA damage recruits MRE11 to break sites (UniProt). Evidence: UniProt P49959, HPA tissue IHC · Supported, HPA ICC-IF · nucleoplasm., Datasheet A32234, PMC4057395, PMC5223425. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MRE11/immunohistochemistry-ihc-guide.